GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
23.75
+0.55 (+2.37%)
As of 1:03PM EST. Market open.
Stock chart is not supported by your current browser
Previous close23.20
Open23.75
Bid0.00 x 0
Ask0.00 x 0
Day's range23.75 - 23.75
52-week range18.90 - 24.20
Volume1,000
Avg. volume3,979
Market cap116.209B
Beta (5Y monthly)0.37
PE ratio (TTM)47.88
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.18 (4.98%)
Ex-dividend date19 Feb 2020
1y target estN/A
  • Once-hot DNA testing unicorn 23andMe is in serious trouble
    Yahoo Finance

    Once-hot DNA testing unicorn 23andMe is in serious trouble

    After a 2018 boom, people are just not buying DNA kits anymore.

  • 2 high yield FTSE 100 dividend shares I’d buy today
    Fool.co.uk

    2 high yield FTSE 100 dividend shares I’d buy today

    Beating the FTSE 100 average is not hard if you know where to look. These high yield dividend shares are also cheap right now, Tom Rodgers says. The post 2 high yield FTSE 100 dividend shares I’d buy today appeared first on The Motley Fool UK.

  • Forget buy-to-let! I’d buy these two shares for an easy life
    Fool.co.uk

    Forget buy-to-let! I’d buy these two shares for an easy life

    Andy Ross thinks these two shares have ample opportunity to grow and make investors wealthy with minimal stress. The post Forget buy-to-let! I’d buy these two shares for an easy life appeared first on The Motley Fool UK.

  • Reuters - UK Focus

    LIVE MARKETS-Closing snapshot: What a recovery

    * European shares up after big pullback on virus scare * STOXX 600 now up 0.8%, FTSE 100 up 0.4% * Wall Street recovers Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan.

  • Reuters - UK Focus

    LIVE MARKETS-About the BoE's 50-50 cliffhanger

    * European shares up after big pullback on virus scare * STOXX 600 now up 0.8%, FTSE 100 up 0.4% * Wall Street recovers Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: thyagaraju.adinarayan.thomsonreuters.com@reuters.net ABOUT THE BOE'S 50-50 CLIFFHANGER (1559 GMT) With cable just below the $1.30 mark for the first time in a week, it seems the cliffhanger about the BoE's will-it, won't-it cut rates on Thursday is only intensifying.

  • Forget cash ISAs! At 4.4% dividend yield, I’ll buy this FTSE 100 stock
    Fool.co.uk

    Forget cash ISAs! At 4.4% dividend yield, I’ll buy this FTSE 100 stock

    GSK is delivering a 4.4% dividend yield. That’s more than double what you would get from a cash ISA.The post Forget cash ISAs! At 4.4% dividend yield, I’ll buy this FTSE 100 stock appeared first on The Motley Fool UK.

  • Reuters - UK Focus

    LIVE MARKETS-Stocks: Who will party on Brexit Friday?

    * European shares up after big pullback on virus scare * STOXX 600 edges 0.3% higher, FTSE 100 up 0.4% * Wall Street set to recover Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Joe Healey and Tom Rosser, investment research analysts at The Share Centre, say the end of the running uncertainty theme, which cost billions to the UK shares, should restore some degree of confidence. Information technology companies, including Sage and FDM Group, could see some gains given the various growth opportunities available in the sector 4.

  • Is There An Opportunity With GlaxoSmithKline plc's (LON:GSK) 36% Undervaluation?
    Simply Wall St.

    Is There An Opportunity With GlaxoSmithKline plc's (LON:GSK) 36% Undervaluation?

    In this article we are going to estimate the intrinsic value of GlaxoSmithKline plc (LON:GSK) by projecting its future...

  • Forget the Cash ISA! I’d invest my first £500 in these FTSE 100 stocks instead
    Fool.co.uk

    Forget the Cash ISA! I’d invest my first £500 in these FTSE 100 stocks instead

    Who says the investor can’t have it all? The post Forget the Cash ISA! I’d invest my first £500 in these FTSE 100 stocks instead  appeared first on The Motley Fool UK.

  • Bayer Looks Well Beyond Its $10 Billion Roundup Payout
    Bloomberg

    Bayer Looks Well Beyond Its $10 Billion Roundup Payout

    (Bloomberg Opinion) -- Investors aren’t waiting for a definitive deal to end the mass of lawsuits against Bayer AG before snapping up the shares. The German life sciences group’s 75 billion euro ($83 billion) market value is up some 26 billion euros in seven months on hopes that thousands of claims related to its glyphosate-based Roundup weedkiller, accused of causing cancer, might be resolved in a settlement. There’s a risk that shareholder expectations are getting carried away.Talks about a deal do appear constructive, based on the tone of limited statements made by the legal mediator Ken Feinberg. Bayer’s lawyers have in some discussions proposed the firm pays $8 billion to settle existing suits and sets aside $2 billion for future claims, Bloomberg News reported Thursday. That was well received by the market, which pushed up Bayer stock as much as 4%. The $10 billion total is consistent with the cost that analysts have put on a settlement.What’s striking about Bayer is that despite its recent rally the stock still trades at a substantial discount to peers, and removing this would be worth much more than the settlement costs being discussed. The company trades at 9 times expected Ebitda. Its pharmaceutical peers command valuations of 11.2 to 17.5 times. Just getting to a valuation matching its cheapest counterparts would add about 20 billion euros of market value, after deducting the estimated cost of ending litigation. A re-rating toward the average of its peer group would see Bayer’s market value rise even more substantially.Investors are right to retain a degree of caution amid the evidence of progress. What Bayer’s lawyers put forward in talks is only a piece of the jigsaw. The number for a final cap on the cost of the glyphosate litigation remains unknown. Bayer has suggested it’s willing to fight if an acceptable figure cannot be agreed. Citing studies, the company says glyphosate is safe when used as directed. There remains a real possibility that the saga endures for longer than investors believe.The other difficult question is whether Bayer deserves a valuation more generous than that commanded by its cheapest peers — such as GlaxoSmithKline Plc, Sanofi and Roche Holding AG. The same management is in place that led Bayer into this mess via an overpriced $66 billion acquisition of U.S. seeds group Monsanto Co. (the owner of Roundup). The touted benefits of that deal, and the logic of marrying crop science and pharmaceuticals, are yet to manifest themselves fully in sales and profit.A premium valuation will need to be earned. From here, the gains to Bayer’s shares will depend on definitive progress both on the litigation — and on operational performance.To contact the author of this story: Chris Hughes at chughes89@bloomberg.netTo contact the editor responsible for this story: James Boxell at jboxell@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Chris Hughes is a Bloomberg Opinion columnist covering deals. He previously worked for Reuters Breakingviews, as well as the Financial Times and the Independent newspaper.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • No savings at 50? I’d buy these 2 FTSE 100 stocks to retire on a rising passive income
    Fool.co.uk

    No savings at 50? I’d buy these 2 FTSE 100 stocks to retire on a rising passive income

    These two FTSE 100 (INDEXFTSE:UKX) dividend heroes could make your retirement more comfortable.The post No savings at 50? I'd buy these 2 FTSE 100 stocks to retire on a rising passive income appeared first on The Motley Fool UK.

  • Reuters - UK Focus

    Roche wins approval for cancer drug Kadcyla in fast-growing China market

    BEIJING/ZURICH Jan 22 (Reuters) - Roche said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another win for the Swiss drugmaker in its second-biggest market where rising demand has helped drive its increased sales and profit. Kadcyla, which also recently won expanded approval in the United States, Canada and Europe for more breast-cancer patients, is an antibody-drug conjugate (ADC), a class of therapies that combine monoclonal antibodies with cytotoxic chemical that in 2019 picked up momentum with a record number of U.S. approvals.

  • Reuters

    'Pay-for-delay' deals over drug generics unlawful - EU court adviser

    An adviser to the European Court of Justice said on Wednesday that an agreement to settle a patent dispute between a pharmaceutical company and generic competitors may harm competition. The case relates to an agreement British drugmaker GlaxoSmithKline struck with generic drug companies to pay them over 50 million pounds to delay the potential entry of independent competitors to its antidepressant Seroxat.

  • Reuters - UK Focus

    "Pay-for-delay" deals over drug generics unlawful- EU court adviser

    An adviser to the European Court of Justice said on Wednesday that an agreement to settle a patent dispute between a pharmaceutical company and generic competitors may harm competition. The case relates to an agreement British drugmaker GlaxoSmithKline struck with generic drug companies to pay them over 50 million pounds to delay the potential entry of independent competitors to its antidepressant Seroxat.

  • Reuters - UK Focus

    Pharma firms not making enough progress against superbugs - report

    Drug companies are not making progress against the spread of antibiotic resistance at a scale and speed great enough to tackle the global health threat posed by superbugs, a key benchmark analysis found on Tuesday. The findings of a second Antimicrobial Resistance (AMR) Benchmark report showed that while a few pharmaceutical companies are expanding their efforts, change is not happening at the scale needed to radically impact the problem. In India, drug resistance exceeds 70% for many widespread bacteria, the AMR report said.

  • Bloomberg

    Glaxo, Pfizer Executives Out of Step on Consumer Unit’s Future

    (Bloomberg) -- U.K. drugmaker GlaxoSmithKline Plc hasn’t made plans to pursue an initial public offering of the consumer-health company it set up with Pfizer Inc. last year, a top executive said, distancing himself from remarks made by Pfizer’s chief executive a day earlier.The comments could expose a lack of communication between the two partners. Pfizer’s Chief Executive Officer Albert Bourla yesterday said he expected Glaxo to pursue an IPO in three to four years.“This is the time that we will be able to exit from this partnership, and I’m sure that this business will have a fantastic IPO,” Bourla said at the J.P. Morgan Healthcare Conference in San Francisco.An IPO isn’t the only option, said David Redfern, Glaxo’s chief strategy officer, in an interview at the meeting. Glaxo said at the time of the deal that it would separate and list the company within three to five years.“Actually we haven’t decided anything,” Redfern said Wednesday. “When we announced the deal, we said we expect it to separate within three years, but actually up to five years. And it’s entirely our decision.”Both Glaxo, the majority owner, and Pfizer, which has about a third of the business, are looking to focus on drug development. Recent shifts in the health-care business and in the broader economy have challenged a model in which drugmakers control every corner of home medicine cabinets.Redfern said the consumer business needed to focus on integration and growing sales, not a spinoff or IPO.“We don’t want it too distracted right now thinking about capital markets,” he said. “Whether it’s an IPO or just a straight spin, all options are on the table. We’ve literally had no discussion” with Pfizer on that topic.With annual sales of about $13 billion, the consumer venture has brought under one roof Advil painkillers, Tums stomach tablets, Sensodyne toothpaste and Nicorette gum.The world’s biggest supplier of over-the-counter medicines will be one of the industry’s only standalones, facing off with companies integrated into larger entities such as Johnson & Johnson, Bayer AG and Procter & Gamble Co.\--With assistance from Mark Schoifet.To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.netFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Pfizer Eyes IPO of Glaxo Consumer Venture in 3 to 4 Years
    Bloomberg

    Pfizer Eyes IPO of Glaxo Consumer Venture in 3 to 4 Years

    (Bloomberg) -- Pfizer Inc. is planning an initial public offering of its consumer-health joint venture with GlaxoSmithKline Plc in three to four years as the two drugmakers turn back toward the lab.Pfizer Chief Executive Officer Albert Bourla discussed the time frame for the IPO at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. The plan provides New York-based Pfizer with a clear exit strategy, he said.The world’s biggest supplier of over-the-counter medicines will be one of the industry’s only standalones, facing off with companies integrated into larger entities such as Johnson & Johnson, Bayer AG and Procter & Gamble Co.With annual sales of about $13 billion, it brings under one roof Advil painkillers, Tums stomach tablets, Sensodyne toothpaste and Nicorette gum.Both Glaxo, the majority owner, and Pfizer, which has about a third of the business, are looking to focus on drug development. Recent shifts in the health-care business and in the broader economy have challenged a model in which drugmakers control every corner of home medicine cabinets.Big pharma companies are increasingly focused on developing high-priced new medicines that draw on cutting-edge research in genetics and other fields. At the same time, the cost of researching new cures is climbing even as insurers and governments demand lower prices.On the consumer-health front, intense price competition online from the likes of Amazon as well as own-brand store products have dented margins in the U.S. and parts of Europe.When the deal was announced, Glaxo said it expected a listing within three years of its close, which took place last August.Glaxo shares rose less than 1% to 1,815 pence in London trading. (Updates with industry context in third and fourth paragraphs)To contact the reporter on this story: Mark Schoifet in New York at mschoifet@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Marthe FourcadeFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Measuring the quality of Glaxosmithkline as an investment
    Stockopedia

    Measuring the quality of Glaxosmithkline as an investment

    A company with a high Quality Rank has strong cash-generation, consistent profits, high rates of return on investment, high margins and robust financial health8230;

  • Have £3k to invest? 3 healthcare stocks I’d buy for 2020
    Fool.co.uk

    Have £3k to invest? 3 healthcare stocks I’d buy for 2020

    Ageing populations and fast-growing emerging markets make these stocks a buy, says Roland Head.

  • 2 FTSE 100 dividend stocks I’d buy and hold for the next 10 years
    Fool.co.uk

    2 FTSE 100 dividend stocks I’d buy and hold for the next 10 years

    These two FTSE 100 (INDEXFTSE:UKX) shares could offer income investing potential in my opinion.

  • I think this FTSE 100 dividend stock could double investors’ money
    Fool.co.uk

    I think this FTSE 100 dividend stock could double investors’ money

    This FTSE 100 company is set to benefit tremendously from global growth, and investors should be well rewarded.

  • Should You Be Excited About GlaxoSmithKline plc's (LON:GSK) 28% Return On Equity?
    Simply Wall St.

    Should You Be Excited About GlaxoSmithKline plc's (LON:GSK) 28% Return On Equity?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs
    Reuters

    Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs

    Drugmakers including Pfizer Inc , GlaxoSmithKline PLC and Sanofi SA are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the price increases will be below 10%, and around half of them are in the range of 4 to 6%, said 3 Axis co-founder Eric Pachman. More price increases are expected to be announced later this week, which could affect the median and range.

  • Does GlaxoSmithKline (LON:GSK) have an economic moat?
    Stockopedia

    Does GlaxoSmithKline (LON:GSK) have an economic moat?

    When it comes to investing, I'm convinced it pays to buy and hold the best quality companies possible. I'm talking about some of the market's most respected na8230;

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more